Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine.

Eliasson DG, El Bakkouri K, Schön K, Ramne A, Festjens E, Löwenadler B, Fiers W, Saelens X, Lycke N.

Vaccine. 2008 Feb 26;26(9):1243-52. doi: 10.1016/j.vaccine.2007.12.027. Epub 2008 Jan 10.

PMID:
18243429
3.
4.

A "universal" human influenza A vaccine.

Fiers W, De Filette M, Birkett A, Neirynck S, Min Jou W.

Virus Res. 2004 Jul;103(1-2):173-6. Review.

PMID:
15163506
5.

Influenza A viruses: why focusing on M2e-based universal vaccines.

Ebrahimi SM, Tebianian M.

Virus Genes. 2011 Feb;42(1):1-8. doi: 10.1007/s11262-010-0547-7. Epub 2010 Nov 17. Review. Erratum in: Virus Genes. 2011 Feb;42(1):9.

PMID:
21082230
6.
7.
8.

Targeted vaccine adjuvants based on modified cholera toxin.

Lycke N.

Curr Mol Med. 2005 Sep;5(6):591-7. Review.

PMID:
16178769
9.

M2e-based universal influenza A vaccine.

Fiers W, De Filette M, El Bakkouri K, Schepens B, Roose K, Schotsaert M, Birkett A, Saelens X.

Vaccine. 2009 Oct 23;27(45):6280-3. doi: 10.1016/j.vaccine.2009.07.007. Review.

PMID:
19840661
10.

Pandemic preparedness: toward a universal influenza vaccine.

Roose K, Fiers W, Saelens X.

Drug News Perspect. 2009 Mar;22(2):80-92. doi: 10.1358/dnp.2009.22.2.1334451. Review.

PMID:
19330167
11.

Soluble recombinant influenza vaccines.

Fiers W, Neirynck S, Deroo T, Saelens X, Jou WM.

Philos Trans R Soc Lond B Biol Sci. 2001 Dec 29;356(1416):1961-3. Review.

12.

Mucosal adjuvants and long-term memory development with special focus on CTA1-DD and other ADP-ribosylating toxins.

Lycke N, Bemark M.

Mucosal Immunol. 2010 Nov;3(6):556-66. doi: 10.1038/mi.2010.54. Epub 2010 Sep 15. Review.

PMID:
20844480
13.

Vaccination of chickens with recombinant Salmonella expressing M2e and CD154 epitopes increases protection and decreases viral shedding after low pathogenic avian influenza challenge.

Layton SL, Kapczynski DR, Higgins S, Higgins J, Wolfenden AD, Liljebjelke KA, Bottje WG, Swayne D, Berghman LR, Kwon YM, Hargis BM, Cole K.

Poult Sci. 2009 Nov;88(11):2244-52. doi: 10.3382/ps.2009-00251. Review.

PMID:
19834072
14.

Mucosal IgA responses in influenza virus infections; thoughts for vaccine design.

van Riet E, Ainai A, Suzuki T, Hasegawa H.

Vaccine. 2012 Aug 31;30(40):5893-900. doi: 10.1016/j.vaccine.2012.04.109. Epub 2012 Jul 24. Review.

PMID:
22835738
15.

From toxin to adjuvant: basic mechanisms for the control of mucosal IgA immunity and tolerance.

Lycke N.

Immunol Lett. 2005 Mar 15;97(2):193-8. Epub 2005 Jan 19. Review.

PMID:
15752558
16.

Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments.

Schotsaert M, De Filette M, Fiers W, Saelens X.

Expert Rev Vaccines. 2009 Apr;8(4):499-508. doi: 10.1586/erv.09.6. Review.

17.

Epitope-based vaccine against influenza.

Ben-Yedidia T, Arnon R.

Expert Rev Vaccines. 2007 Dec;6(6):939-48. Review.

PMID:
18034655
18.

Towards an epitope-based human vaccine for influenza.

Ben-Yedidia T, Arnon R.

Hum Vaccin. 2005 May-Jun;1(3):95-101. Epub 2005 May 15. Review.

PMID:
17012851
19.

Influenza virosomes as a combined vaccine carrier and adjuvant system for prophylactic and therapeutic immunizations.

Moser C, Amacker M, Kammer AR, Rasi S, Westerfeld N, Zurbriggen R.

Expert Rev Vaccines. 2007 Oct;6(5):711-21. Review.

PMID:
17931152
20.

Adjuvants modulating mucosal immune responses or directing systemic responses towards the mucosa.

Cox E, Verdonck F, Vanrompay D, Goddeeris B.

Vet Res. 2006 May-Jun;37(3):511-39. Epub 2006 Apr 14. Review.

Supplemental Content

Support Center